Resistentia Pharmaceuticals’ drug will be produced for use in Phase III trials.
Biovitrum will develop and manufature Resistentia Pharmaceuticals’ new protein-based allergy drug, RES 08, for use in Phase III trials, under an agreement between the companies.
Biovitrum will expand on the existing process for the biotechnical manufacturing of RES 08 to a standard that meets the high demands of a Phase III trial and manufacture sufficient amounts of the drug for the trial. The project will run for more than two years beginning in November.
